Summary of Autolus Therapeutics Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $45.7 million for Q2 2026, up from $20.9 million in Q2 2025 and $26.2 million in Q1 2026.

First Half Revenue: Total of $71.9 million, nearing the full year revenue of $72 million from the previous year.

Gross Margin: Improved to 55% in Q2 2026, up from 6% in Q1 2026 and negative in all quarters of 2025.

Operating Loss: $43.8 million for Q2 2026, improved from $61.2 million in Q2 2025.

Net Loss: $39.1 million for Q2 2026, compared to $47.9 million in Q2 2025.

Cash Position: $201.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing runway into Q2 2028.

2Strategic Updates and Business Highlights

AUCATZYL Launch: Strong sales growth in the U.S. and U.K., with over 80 treatment centers activated and plans to exceed 90 by year-end.

Market Expansion: Positive physician feedback and adoption rates, particularly in the U.K. market, which is still early in its launch phase.

Operational Improvements: Increased production volumes and efficiency in manufacturing, contributing to gross margin improvements.

Pipeline Developments: Ongoing studies for obe-cel in various indications, including pediatric ALL and lupus nephritis, with key data expected in 2027 and 2028.

3Forward Guidance and Outlook

Revenue Guidance: Increased full-year revenue guidance to $140 million - $150 million, up from the previous range of $120 million - $135 million.

Gross Margin Target: Aiming for gross margins of 65% to 70% for the ALL business within 12 to 18 months.

Clinical Milestones: Anticipated data releases from several pivotal studies, including pediatric ALL and lupus nephritis, expected to drive future growth.

4Bad News, Challenges, or Points of Concern

Seasonality Risks: The company acknowledged potential seasonality effects that could impact revenue in the latter half of the year.

Operational Costs: Increased SG&A expenses to $41.2 million in Q2 2026, up from $30.3 million in the same period last year, driven by commercialization efforts and one-time restructuring costs.

Market Competition: The need to maintain and grow market share in a competitive CAR T landscape, with ongoing efforts to expand physician adoption and referral patterns.

5Notable Q&A Insights

Sales Confidence: Management expressed confidence in sustaining sales momentum but acknowledged potential fluctuations due to seasonality.

Gross Margin Trajectory: The company expects continued improvement in gross margins driven by increased production efficiency and volume, with a target of 65% to 70% in the next 12 to 18 months.

U.K. Market Contribution: Initial U.K. sales are modest, contributing less than 10% of U.S. sales, but strong momentum is noted with plans for further center activations.

Center Utilization: Most activated centers have treated patients, indicating a quick transition from activation to treatment, which is crucial for ongoing adoption. Overall, Autolus Therapeutics reported a strong quarter with significant revenue growth and operational improvements, while also navigating challenges related to market competition and cost management. The company remains optimistic about its future growth potential and pipeline advancements.